These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28064163)

  • 41. The mineralocorticoid receptor blocker spironolactone lowers plasma interferon-γ and interleukin-6 in patients with type 2 diabetes and treatment-resistant hypertension.
    Thangaraj SS; Oxlund CS; Fonseca MPD; Svenningsen P; Stubbe J; Palarasah Y; Ketelhuth DFJ; Jacobsen IA; Jensen BL
    J Hypertens; 2022 Jan; 40(1):153-162. PubMed ID: 34843183
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor.
    Ogawa S; Takeuchi K; Mori T; Nako K; Ito S
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):477-9. PubMed ID: 16700881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Albuminuria is associated with an increased prostasin in urine while aldosterone has no direct effect on urine and kidney tissue abundance of prostasin.
    Oxlund C; Kurt B; Schwarzensteiner I; Hansen MR; Stæhr M; Svenningsen P; Jacobsen IA; Hansen PB; Thuesen AD; Toft A; Hinrichs GR; Bistrup C; Jensen BL
    Pflugers Arch; 2017 Jun; 469(5-6):655-667. PubMed ID: 28233126
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy.
    Chen Y; Liu P; Chen X; Li Y; Zhang F; Wang Y
    Am J Med Sci; 2018 May; 355(5):418-424. PubMed ID: 29753370
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.
    Sato A; Fukuda S
    Hypertens Res; 2013 Oct; 36(10):879-84. PubMed ID: 23864056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy.
    Medeiros M; Velásquez-Jones L; Hernández AM; Ramón-García G; Valverde S; Fuentes Y; Vargas A; Patiño M; Pérez-Villalva R; Ortega-Trejo JA; Barrera-Chimal J; Bobadilla NA
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1291-1300. PubMed ID: 28536123
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension.
    Sawai T; Dohi K; Fujimoto N; Okubo S; Isaka N; Ichikawa T; Makino K; Okamoto S; Koyabu S; Kitamura T; Ogura T; Yamada T; Tamaru S; Nishikawa M; Nakamura M; Ito M;
    J Clin Hypertens (Greenwich); 2017 Oct; 19(10):990-998. PubMed ID: 28849629
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study.
    Rachmani R; Slavachevsky I; Amit M; Levi Z; Kedar Y; Berla M; Ravid M
    Diabet Med; 2004 May; 21(5):471-5. PubMed ID: 15089793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Spironolactone reduces blood pressure and albuminuria of obese hypertensive patients with metabolic syndrome].
    Ezequiel DG; Paula RB; Lovisi JC; Bicalho TC; Souza Fillho SF; Rezende Sde P; Costa MB
    J Bras Nefrol; 2013; 35(1):69-72. PubMed ID: 23598755
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients.
    Morita R; Tsukamoto S; Obata S; Yamada T; Uneda K; Uehara T; Rehman ME; Azushima K; Wakui H; Tamura K
    Diabetes Obes Metab; 2023 May; 25(5):1271-1279. PubMed ID: 36633511
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of spironolactone for 1 yr on endothelial function and vascular inflammation biomarkers in renal transplant recipients.
    Mortensen LA; Bistrup C; Stubbe J; Carlström M; Checa A; Wheelock CE; Palarasah Y; Bladbjerg EM; Thiesson HC; Jensen BL
    Am J Physiol Renal Physiol; 2019 Sep; 317(3):F529-F539. PubMed ID: 31166706
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors for the development of microalbuminuria and interaction with renal function.
    Chatzikyrkou C; Menne J; Izzo J; Viberti G; Rabelink T; Ruilope LM; Rump C; Mertens PR; Haller H
    J Hypertens; 2017 Dec; 35(12):2501-2509. PubMed ID: 29035939
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) Trial.
    Rajagopalan S; Alaiti MA; Broadwater K; Goud A; Gaztanaga J; Connelly K; Fares A; Shirazian S; Kreatsoulas C; Farkouh M; Dobre M; Fink JC; Weir MR
    Clin Cardiol; 2017 Sep; 40(9):633-640. PubMed ID: 28555959
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease.
    Rodríguez-Ortiz ME; Pontillo C; Rodríguez M; Zürbig P; Mischak H; Ortiz A
    Sci Rep; 2018 Oct; 8(1):15940. PubMed ID: 30374033
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence study.
    Goldshtein I; Karasik A; Melzer-Cohen C; Engel SS; Yu S; Sharon O; Brodovicz K; Gadir N; Katzeff HL; Radican L; Chodick G; Shalev V; Tunceli K
    J Diabetes Complications; 2016; 30(7):1354-9. PubMed ID: 27320183
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial.
    Brandt-Jacobsen NH; Johansen ML; Rasmussen J; Forman JL; Holm MR; Faber J; Rossignol P; Schou M; Kistorp C
    Diabetes Metab; 2021 Jul; 47(4):101190. PubMed ID: 32919068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA
    Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study.
    Bobrie G; Frank M; Azizi M; Peyrard S; Boutouyrie P; Chatellier G; Laurent S; Menard J; Plouin PF
    J Hypertens; 2012 Aug; 30(8):1656-64. PubMed ID: 22728905
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes.
    Pena MJ; Jankowski J; Heinze G; Kohl M; Heinzel A; Bakker SJ; Gansevoort RT; Rossing P; de Zeeuw D; Heerspink HJ; Jankowski V
    J Hypertens; 2015 Oct; 33(10):2123-32. PubMed ID: 26237555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression.
    Gonzalez-Calero L; Martin-Lorenzo M; de la Cuesta F; Maroto AS; Baldan-Martin M; Ruiz-Hurtado G; Pulido-Olmo H; Segura J; Barderas MG; Ruilope LM; Vivanco F; Alvarez-Llamas G
    Cardiovasc Diabetol; 2016 Jan; 15():8. PubMed ID: 26772976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.